zur Navigation zum Inhalt
Onkologie 12. Oktober 2016

Practice changing information in aggressive lymphoma, ASH 2015

Out of the numerous papers dealing with lymphoma at the American Society of Hematology (ASH) 2015 meeting, three could change clinical practice. The DA-EPOCH-R regimen has improved the evidence for efficacy in Burkitt lymphoma. For lymphoproliferative disease after solid organ transplantation rituximab is a reasonable first-line treatment and nonresponders can be salvaged with R‑CHOP. For anaplastic large cell lymphoma the addition of etoposide to the CHOP regimen is an option. However, better regimens with new drugs are eagerly awaited.

Zu diesem Thema wurden noch keine Kommentare abgegeben.

Mehr zum Thema

<< Seite 1 >>

Medizin heute

Aktuelle Printausgaben